Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2162-3619
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort ; volume:8 ; number:1 ; day:11 ; month:10 ; year:2019 ; pages:1-6 ; date:12.2019
Experimental hematology & oncology ; 8, Heft 1 (11.10.2019), 1-6, 12.2019
- Urheber
-
Fairclough, Stephen R.
Kiedrowski, Lesli A.
Lin, Jessica J.
Zelichov, Ori
Tarcic, Gabi
Stinchcombe, Thomas E.
Odegaard, Justin I.
Lanman, Richard B.
Shaw, Alice T.
Nagy, Rebecca J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40164-019-0148-7
- URN
-
urn:nbn:de:101:1-2020022304513218193690
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Fairclough, Stephen R.
- Kiedrowski, Lesli A.
- Lin, Jessica J.
- Zelichov, Ori
- Tarcic, Gabi
- Stinchcombe, Thomas E.
- Odegaard, Justin I.
- Lanman, Richard B.
- Shaw, Alice T.
- Nagy, Rebecca J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Über die Proteinbindung frei zirkulierender DNA (cfDNA)
Analyse zellfreier DNA (cfDNA) in liquid biopsies von neuroonkologischen Tumoren
Biospecimen Science of Blood for cfDNA Genetic Analyses
Deep cfDNA fragment end profiling enables cancer detection
Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
The non-vesicle cell-free DNA (cfDNA) induces cell transformation associated with horizontal DNA transfer
Prädiktion der Fetalen Fraktion im Rahmen eines cfDNA Tests
Hypertensive disorders of pregnancy share common cfDNA methylation profiles
Validating quantitative PCR assays for cfDNA detection without DNA extraction in exercising SLE patients
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
CF
CF...
Über die Proteinbindung frei zirkulierender DNA (cfDNA)
Analyse zellfreier DNA (cfDNA) in liquid biopsies von neuroonkologischen Tumoren
Biospecimen Science of Blood for cfDNA Genetic Analyses
Deep cfDNA fragment end profiling enables cancer detection
Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
The non-vesicle cell-free DNA (cfDNA) induces cell transformation associated with horizontal DNA transfer
Prädiktion der Fetalen Fraktion im Rahmen eines cfDNA Tests
Hypertensive disorders of pregnancy share common cfDNA methylation profiles
Validating quantitative PCR assays for cfDNA detection without DNA extraction in exercising SLE patients
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
CF
CF...
Über die Proteinbindung frei zirkulierender DNA (cfDNA)
Analyse zellfreier DNA (cfDNA) in liquid biopsies von neuroonkologischen Tumoren
Biospecimen Science of Blood for cfDNA Genetic Analyses
Deep cfDNA fragment end profiling enables cancer detection
Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
The non-vesicle cell-free DNA (cfDNA) induces cell transformation associated with horizontal DNA transfer
Prädiktion der Fetalen Fraktion im Rahmen eines cfDNA Tests
Hypertensive disorders of pregnancy share common cfDNA methylation profiles
Validating quantitative PCR assays for cfDNA detection without DNA extraction in exercising SLE patients
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
CF